Abstract:AIM: To produce high-quality polyclonal antibody to lysosome-associated protein transmembrane 4B-35 and to identify LAPTM4B-35 expression in cancer tissues and its correlation with differentiation status of hepatocellular carcinoma (HCC).METHODS: The 297 bp 5 ' end of LAPTM4B cDNA was obtained by PCR and inserted into prokaryotic expression vector pGEX-KG. Then the recombinant pGEX-KG-N1-99 was transformed into E.coli JM109 to express GST-fusion protein. The fusion protein was purified by glutathione sepharose (TM) 4B agarose. The purified GST-LAPTM4B-N1-99 was characterized by SDS-PAGE, and used to immunize rabbits. The titer and specificity of antisera were detected by ELISA and Western blot, respectively. The correlation between the expression levels of LAPTM4B-35 and the differentiation status of HCC was analyzed via Western blot. The expression of LAPTM4B-35 in HCC and other six cancer tissues was investigated via tissue chip and immunohistochemical analysis.RESULTS: About 6.2 mg of pure GST-LAPTM4B-N1-99 was isolated from 1 L of bacteria. The GST-LAPTM4B-N1-99 produced high titer antisera in rabbits and showed good immunity. Western blot showed specific reactions for the antibody to the LAPTM4B-35 in the total proteins from HCC tissues and BEL-7402 cells, also to the fusion protein purified or in the transformed bacteria. LAPTM4B-35 was remarkably expressed in several cancers, such as HCC, breast cancer, gastric carcinoma, lung cancer, and colon carcinoma, but not commonly expressed in esophageal cancer and rectum carcinoma. Notably, the expression levels of LAPTM4B-35 were significantly and inversely correlated to the differentiation of HCCs in a 20 case analysis.CONCLUSION: Specific polyclonal antibody (LAPTM4B-N1-99-pAb) to LAPTM4B-35 was produced. It identified the expression of LAPTM4B-35 in some cancer tissues originated from single layer cuboidal and columnar epithelial cells and firmly demonstrated that the expression of LAPTM4B-35 in HCC was inversely correlated with the differentiation of HCC. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.

LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.

BC047440 Overexpression is a Risk Factor for Tumor Invasion and Poor Prognosis in Hepatocellular Carcinoma.

Expression of LAPTM4B-35: a Novel Marker of Progression, Invasiveness and Poor Prognosis of Extrahepatic Cholangiocarcinoma.

Correlation of Lysosome-Associated Protein Transmembrane-4Β Gene Overexpression with the Malignant Phenotypes of Hepatocellular Carcinoma.

Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis

Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma.

Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma.

Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.

Laptm4b-35, A Cancer-Related Gene, Is Associated With Poor Prognosis In Tnm Stages I-Iii Gastric Cancer Patients

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Laptm4b-35 Expression Was Correlated with Favorable Post-Operation Survival in Pancreatic Cancer Patients

Overexpression Of Laptm4b-35 In Cervical Carcinoma: A Clinicopathologic Study

Identification of CCDC115 As an Adverse Prognostic Biomarker in Liver Cancer Based on Bioinformatics and Experimental Analyses

LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma

Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line.

LAPTM4B Facilitates Tumor Growth and Induces Autophagy in Hepatocellular Carcinoma

Molecular cloning and characterization of LAPTM4B , a novel gene upregulated in hepatocellular carcinoma

Laptm4b-35 Overexpression Is An Independent Prognostic Marker In Endometrial Carcinoma

High Expression Levels of CLEC4M Indicate Poor Prognosis in Patients with Hepatocellular Carcinoma

Expression of Lysosome-Associated Protein Transmembrane 4B-35 in Cancer and Its Correlation with the Differentiation Status of Hepatocellular Carcinoma

Overexpression of Laptm4b is Correlated with Tumor Angiogenesis and Poor Prognosis in Non-Small Cell Lung Cancer